MM 310

Drug Profile

MM 310

Alternative Names: MM-310

Latest Information Update: 31 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California at Los Angeles
  • Developer Merrimack Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Eph family receptor modulators; EphA2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 23 Mar 2017 Phase-I clinical trials in Solid tumours (Second-line therapy or greater) in USA (IV) (NCT03076372)
  • 09 Mar 2017 MM-310 licensed to Merrimack Pharmaceuticals worldwide (Merrimack Pharmaceuticals Annual Report, March 2017)
  • 09 Mar 2017 Merrimack Pharmaceuticals has patent protection for MM-310 in USA, Europe and other countries (Merrimack Pharmaceuticals Annual Report, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top